GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

--In Europe, the Stoxx Europe 600 climbed 0.3% in morning trading. France's CAC 40 increased 0.4% and Germany's DAX rose 0.3%. Vestas Wind Systems added 11.6% after an upgrade. GSK lost over 6.0%, and ...

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and ...

On Tuesday, Berenberg analysts downgraded GlaxoSmithKline (NYSE: GSK) stock from Buy to Hold, maintaining a price target of £16.00. The decision comes as GSK (LON: GSK)’s share price surged 25.94% ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.